About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker AZN · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Oct 23, 2026SYMBICORT AEROSPHERE
BUDESONIDE; FORMOTEROL FUMARATE
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA216579 ↗
Oct 21, 2026ULTOMIRIS
RAVULIZUMAB-CWVZ
AZN
Alexion Pharm
Biologic (BLA), supplement
Efficacy
BLA761108 ↗
Letter or label ↗
Oct 21, 2026SOLIRIS
ECULIZUMAB
AZN
Alexion Pharm
Biologic (BLA), supplement
REMS
BLA125166 ↗
Letter or label ↗
Oct 8, 2026BREZTRI AEROSPHERE
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE
AZN
Astrazeneca AB
New drug (NDA)
Type 5 - New Formulation or New Manufac…
NDA220290 ↗
Sep 23, 2026CRESTOR
ROSUVASTATIN CALCIUM
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA021366 ↗
Sep 16, 2026TRUQAP
CAPIVASERTIB
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA218197 ↗
Sep 14, 2026TAGRISSO
OSIMERTINIB MESYLATE
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA208065 ↗
Sep 14, 2026TAGRISSO
OSIMERTINIB MESYLATE
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA208065 ↗
Sep 4, 2026ETCAMAH
CAMIZESTRANT
AZN
Astrazeneca
New drug (NDA)
Type 1 - New Molecular Entity
NDA220359 ↗
Aug 31, 2026IMJUDO
TREMELIMUMAB-ACTL
AZN
Astrazeneca AB
Biologic (BLA), supplement
Labeling
BLA761289 ↗
Aug 31, 2026IMFINZI
DURVALUMAB
AZN
Astrazeneca UK Ltd
Biologic (BLA), supplement
Labeling
BLA761069 ↗
Aug 11, 2026XIGDUO XR
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
AZN
Astrazeneca AB
New drug (NDA), supplement
Labeling
NDA205649 ↗
Aug 11, 2026XIGDUO XR
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
AZN
Astrazeneca AB
New drug (NDA), supplement
Labeling
NDA205649 ↗
Aug 11, 2026KOMBIGLYZE XR
METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
AZN
Astrazeneca AB
New drug (NDA), supplement
Labeling
NDA200678 ↗
Aug 7, 2026SAPHNELO
ANIFROLUMAB-FNIA
AZN
Astrazeneca AB
Biologic (BLA), supplement
Labeling
BLA761123 ↗
Jun 30, 2026SOLIRIS
ECULIZUMAB
AZN
Alexion Pharm
Biologic (BLA), supplement
Labeling
BLA125166 ↗
Jun 12, 2026TRUQAP
CAPIVASERTIB
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA218197 ↗
Jun 3, 2026QTERN
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
AZN
Astrazeneca AB
New drug (NDA), supplement
Labeling
NDA209091 ↗
Jun 3, 2026FARXIGA, DAPAGLIFLOZIN
DAPAGLIFLOZIN
AZN
Astrazeneca AB
New drug (NDA), supplement
Labeling
NDA202293 ↗
Jun 1, 2026ULTOMIRIS
RAVULIZUMAB-CWVZ
AZN
Alexion Pharm
Biologic (BLA), supplement
REMS
BLA761108 ↗
Letter or label ↗
Jun 1, 2026SOLIRIS
ECULIZUMAB
AZN
Alexion Pharm
Biologic (BLA), supplement
REMS
BLA125166 ↗
Letter or label ↗
May 28, 2026IMFINZI
DURVALUMAB
AZN
Astrazeneca UK Ltd
Biologic (BLA), supplement
Efficacy
BLA761069 ↗
May 27, 2026TRUQAP
CAPIVASERTIB
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA218197 ↗
May 26, 2026KOSELUGO
SELUMETINIB; SELUMETINIB SULFATE
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA219943 ↗
Letter or label ↗
May 26, 2026KOSELUGO
SELUMETINIB SULFATE
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA213756 ↗
Letter or label ↗
May 15, 2026BAXFENDY
BAXDROSTAT
AZN
Astrazeneca AB
New drug (NDA)
Type 1 - New Molecular Entity
NDA219878 ↗
May 13, 2026FASENRA
BENRALIZUMAB
AZN
Astrazeneca AB
Biologic (BLA), supplement
Efficacy
BLA761070 ↗
May 7, 2026BRILINTA
TICAGRELOR
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA022433 ↗
Apr 29, 2026CRESTOR
ROSUVASTATIN CALCIUM
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA021366 ↗
Apr 27, 2026SYMBICORT AEROSPHERE
BUDESONIDE; FORMOTEROL FUMARATE
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA216579 ↗
Apr 27, 2026BREZTRI AEROSPHERE
BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE
AZN
Astrazeneca AB
New drug (NDA), supplement
Efficacy
NDA212122 ↗
Apr 24, 2026SAPHNELO
ANIFROLUMAB-FNIA
AZN
Astrazeneca AB
Biologic (BLA)
Type 5 - New Formulation or New Manufac…
BLA761451 ↗
Apr 15, 2026WAINUA
EPLONTERSEN SODIUM
AZN
Astrazeneca AB
New drug (NDA), supplement
Efficacy
NDA217388 ↗
Letter or label ↗
Apr 7, 2026BEYFORTUS
NIRSEVIMAB-ALIP
AZN
Astrazeneca AB
Biologic (BLA), supplement
Labeling
BLA761328 ↗
Feb 19, 2026CALQUENCE
ACALABRUTINIB MALEATE
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA216387 ↗
Letter or label ↗
Feb 19, 2026CALQUENCE
ACALABRUTINIB
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA210259 ↗
Letter or label ↗
Dec 17, 2025WAINUA
EPLONTERSEN SODIUM
AZN
Astrazeneca AB
New drug (NDA), supplement
Labeling
NDA217388 ↗
Nov 25, 2025IMFINZI
DURVALUMAB
AZN
Astrazeneca UK Ltd
Biologic (BLA), supplement
Efficacy
BLA761069 ↗
Nov 19, 2025KOSELUGO
SELUMETINIB; SELUMETINIB SULFATE
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA219943 ↗
Nov 19, 2025KOSELUGO
SELUMETINIB SULFATE
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA213756 ↗
Nov 14, 2025TRUQAP
CAPIVASERTIB
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA218197 ↗
Oct 20, 2025BEYFORTUS
NIRSEVIMAB-ALIP
AZN
Astrazeneca AB
Biologic (BLA), supplement
Efficacy
BLA761328 ↗
Oct 17, 2025TEZSPIRE
TEZEPELUMAB-EKKO
AZN
Astrazeneca AB
Biologic (BLA), supplement
Efficacy
BLA761224 ↗
Sep 26, 2025ULTOMIRIS
RAVULIZUMAB-CWVZ
AZN
Alexion Pharm
Biologic (BLA), supplement
Manufacturing (CMC)
BLA761108 ↗
Sep 15, 2025AIRSUPRA
ALBUTEROL SULFATE; BUDESONIDE
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA214070 ↗
Sep 10, 2025KOSELUGO
SELUMETINIB; SELUMETINIB SULFATE
AZN
Astrazeneca
New drug (NDA)
Type 3 - New Dosage Form
NDA219943 ↗
Sep 10, 2025KOSELUGO
SELUMETINIB SULFATE
AZN
Astrazeneca
New drug (NDA), supplement
Efficacy
NDA213756 ↗
Sep 2, 2025BYETTA
EXENATIDE SYNTHETIC
AZN
Astrazeneca AB
New drug (NDA), supplement
Labeling
NDA021773 ↗
Jul 10, 2025LYNPARZA
OLAPARIB
AZN
Astrazeneca
New drug (NDA), supplement
Labeling
NDA208558 ↗
Jun 27, 2025VOYDEYA
DANICOPAN
AZN
Alexion Pharmaceuticals Inc
New drug (NDA), supplement
REMS
NDA218037 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 7:16 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates